Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fingolimod for COVID-19-induced cytokine storm
IRCT20200317046797N2Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fingolimod in coronavirus pneumonia (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Change in pneumonia severity on CT scan, Hospitalization period and 4 more. Started Apr 2020; status: completed.
02
Drugs
fingolimod
03
Conditions
coronavirus pneumonia
Beyond the preview
Go deeper on IRCT20200317046797N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200317046797N2.